...
首页> 外文期刊>Biologicals: Journal of the International Association of Biological Standardization >Antibody responses of Macaca fascicularis against a new inactivated polio vaccine derived from Sabin strains (sIPV) in DTaP-sIPV vaccine
【24h】

Antibody responses of Macaca fascicularis against a new inactivated polio vaccine derived from Sabin strains (sIPV) in DTaP-sIPV vaccine

机译:猕猴对DTaP-sIPV疫苗中Sabin株(sIPV)衍生的新型灭活脊髓灰质炎疫苗的抗体反应

获取原文
获取原文并翻译 | 示例
           

摘要

Antibody responses of Macaca fascicularis against a new tetravalent vaccine composed of diphtheria toxoid, tetanus toxoid, acellular pertussis antigens, and inactivated poliovirus derived from Sabin strains (sIPV) was investigated to predict an optimal dose of sIPV in a new tetravalent vaccine (DTaP-sIPV) prior to conducting a dose-defined clinical study. Monkeys were inoculated with DTaP-sIPVs containing three different antigen units of sIPVs: Vaccine A (types 1:2:3 = 3:100:100 DU), Vaccine B (types 1:2:3 = 1.5:50:50 DU), and Vaccine C (types 1:2:3 = 0.75:25:25 DU). There was no difference in the average titers of neutralizing antibody against the attenuated or virulent polioviruses between Vaccines A and B. The average neutralizing antibody titers of Vaccine C tended to be lower than those of Vaccines A and B. The sIPV antigens did not affect the anti-diphtheria or anti-tetanus antibody titers of DTaP-sIPV. Furthermore, the average neutralizing antibody titers of Vaccine A against the attenuated and virulent polioviruses were comparable between M. fascicularis and humans. These results suggest that M. fascicularis may be a useful animal model for predicting the antibody responses to sIPVs in humans, and that it may be likely to reduce the amount of sIPVs contained in DTaP-sIPVs, even for humans.
机译:研究了猕猴对一种新的由白喉类毒素,破伤风类毒素,无细胞百日咳抗原组成的新四价疫苗和源自萨宾菌株(sIPV)的灭活脊髓灰质炎病毒的抗体反应,以预测新四价疫苗(DTaP-sIPV)中sIPV的最佳剂量),然后再进行剂量定义的临床研究。用含有三种不同sIPV抗原单位的DTaP-sIPV接种猴子:疫苗A(类型1:2:3 = 3:100:100 DU),疫苗B(类型1:2:3 = 1.5:50:50 DU)和疫苗C(类型1:2:3 = 0.75:25:25 DU)。疫苗A和B之间针对减毒或强毒脊髓灰质炎病毒的中和抗体的平均滴度没有差异。疫苗C的平均中和抗体滴度往往低于疫苗A和B。sIPV抗原不影响疫苗DTaP-sIPV的抗白喉或抗破伤风抗体滴度。此外,针对弱毒和脊髓灰质炎病毒的疫苗A的平均中和抗体效价在法氏杆菌和人之间是可比的。这些结果表明,筋膜分枝杆菌可能是用于预测人对sIPV的抗体反应的有用的动物模型,并且即使对于人类,它也可能减少包含在DTaP-sIPV中的sIPV的量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号